- $22.33m
- -$8.09m
- $8.98m
InspireMD Inc reports results for the quarter ended in December - Earnings Summary
Brief: InspireMD Q4 revenue USD 1.761 million
Brief: InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard Neuroprotection System
Brief: InspireMD Appoints Pete Ligotti as EVP of North America
Brief: InspireMD Announces Issuance Of U.S. Patent Covering Its SwitchGuard Neuroprotection System
Brief: Inspiremd's Cash, Cash Equivalents And Short-Term Investments And Bank Deposits As Of September 30, 2023, Were $43.0 Million
Brief: InspireMD Q3 basic EPS USD -0.15
InspireMD Inc expected to post a loss of 15 cents a share - Earnings Preview
Brief: InspireMD Presents Positive 30-Day Follow-Up Results From The C-Guardians U.S. IDE Clinical Trial At VIVA23
InspireMD Inc reports results for the quarter ended in June - Earnings Summary
Brief: InspireMD Q2 Basic EPS USD -0.24
InspireMD Inc expected to post a loss of 30 cents a share - Earnings Preview
Silk Road tumbles, InspireMD rises after Medicare coverage proposal for stents
Brief: InspireMD Announces Completion Of Enrollment In C-Guardians U.S. Investigational Device Exemption Clinical Trial
Brief: InspireMD Inc Files For Stock Offering Of Up To 77.5 Million Shares Of Common Stock By Selling Stockholders - SEC Filing
InspireMD Inc reports results for the quarter ended in March - Earnings Summary
Brief: InspireMD Reports First Quarter 2023 Financial Results And Provides Business Update
InspireMD Inc expected to post a loss of 68 cents a share - Earnings Preview
InspireMD Inc expected to post a loss of 68 cents a share - Earnings Preview